The vaccine will contain tumor lysate obtained from the patient’s own melanoma tumor cells combined with other immunostimulatory agents such as CpG and granulocyte-macrophage colony-stimulating factor (GM-CSF). The gene discussed is CSF2; the disease is melanoma.